Short interest for Novo Nordisk gives investors a sense of the degree to which investors are betting on the decline of Novo Nordisk's stock. Short interest data is updated every two weeks.

Novo Nordisk Stock (NYSE:NVO), Short Interest Report

Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Bernie Sanders Ozempic

Biotech

Large Cap

News

Health Care

Legal

Movers

General

Senate Committee probes Novo Nordisk&#39;s pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could impact millions, tackling accessibility challenges amidst rising costs.

What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk

weight-loss-Photo by Vidmir Rais via Pixabay

CAVA

SBUX

Discover how GLP-1 drugs reshape consumer spending in food industries. Novo Nordisk&#39;s Wegvoy and Eli Lilly&#39;s Zepbound gain traction, altering dining habits.

Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly&#39;s Weight Loss Drugs Reshaping Food Spending

Ozempic maker Novo Nordisk

Novo Nordisk&#39;s acquisition of Cardior Pharmaceuticals clears regulatory hurdles, advancing cardiovascular treatment development with CDR132L. Learn about the promising phase 2 trials and strategic expansion. Deal expected to close Q2 2024.

German Authority Gives Go Ahead To Novo Nordisk&#39;s Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline

Novo Nordisk A/S

Novo Resources Corp Warrants (27/08/2023)

Novo Integrated Sciences, Inc. - Common Stock

Novo Integrated Sciences Inc

Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 71% leaning bullish and 19% bearish. Among these notable options, 4 are puts, totaling $206,445, and 17 are calls, amounting to $1,195,302.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $97.5 to $150.0 for Novo Nordisk over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Novo Nordisk options trades today is 1993.72 with a total volume of 2,923.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Novo Nordisk's big money trades within a strike price range of $97.5 to $150.0 over the last 30 days.
<h3>Novo Nordisk Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714417257_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.8</td>
<td>$14.35</td>
<td>$14.8</td>
<td>$130.00</td>
<td>$371.2K</td>
<td>2.3K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.5</td>
<td>$7.35</td>
<td>$7.5</td>
<td>$150.00</td>
<td>$262.5K</td>
<td>2.0K</td>
<td style="text-align: right;">383</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.51</td>
<td>$2.38</td>
<td>$2.38</td>
<td>$97.50</td>
<td>$107.1K</td>
<td>770</td>
<td style="text-align: right;">450</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$5.85</td>
<td>$5.65</td>
<td>$5.85</td>
<td>$125.00</td>
<td>$58.5K</td>
<td>1.3K</td>
<td style="text-align: right;">101</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/19/24</td>
<td>$1.66</td>
<td>$1.58</td>
<td>$1.58</td>
<td>$150.00</td>
<td>$54.6K</td>
<td>1.4K</td>
<td style="text-align: right;">349</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Novo Nordisk</h3>
<ul>
<li>Currently trading with a volume of 1,266,034, the NVO's price is down by -0.01%, now at $126.84. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 3 days.</li>
</ul>
<h3>Professional Analyst Ratings for Novo Nordisk</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $160.75.
<ul>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. </li>
<li>An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $160. </li>
<li>In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $160. </li>
<li>Reflecting concerns, an analyst from BMO Capital lowers its rating to Outperform with a new price target of $163.</li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Novo Nordisk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Decoding Novo Nordisk's Options Activity: What's the Big Picture?

FDA Says Novo Nordisk's Wegovy, Injection, 1.7 mg/.75 ml (NDC 0169-4517-14) Is Available

FDA Says Novo's Wegovy, Injection, .25 mg/.5 ml (NDC 0169-4525-14) Under Limited Availability With Estimated Shortage Duration TBD; Wegovy, Injection, .5 mg/.5 ml (NDC 0169-4505-14) Under Limited Availability With Estimated Shortage Duration TBD; Wegovy, Injection, 1 mg/.5 ml (NDC 0169-4501-14) Limited Availability With Estimated Shortage Duration TBD

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 10 years by 8.67% on an annualized basis producing an average annual return of 19.12%. Currently, Novo Nordisk has a market capitalization of $565.70 billion. 
Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 10 years ago, it would be worth $5,586.46 today based on a price of $126.80 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1714141814_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years

The Senate Committee on Health, Education, Labor, and Pensions is reportedly scrutinizing &nbsp;Novo Nordisk&nbsp;A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) &#8216;s pricing strategies, particularly those of its diabetes and obesity&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37989566/how-much-does-it-cost-to-make-novo-nordisks-ozempic-shockingly-low-against-1-000-price-tag-study-" rel="noreferrer noopener">medications, Ozempic and Wegovy</a>.
Senator Bernie Sanders emphasized the necessity of reducing prices to ensure accessibility for consumers and sustainability for governments.
Senator Sanders penned a letter to Novo Nordisk&#8217;s CEO, Lars Fruergaard Jorgensen, demanding internal communications regarding the pricing discrepancies between the U.S. and other countries.&nbsp;
The committee questioned why Wegovy, containing the same compound as Ozempic, bears a higher price tag, the New York Times&nbsp;<a target="_blank" href="https://www.nytimes.com/2024/04/24/well/live/ozempic-cost-senate.html?searchResultPosition=1" rel="noreferrer noopener">noted</a>. A response has been requested by May 8.
Senator Sanders also intended to investigate&nbsp;Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), the manufacturer of rival medications, Mounjaro and Zepbound, to address industry-wide pricing concerns.&nbsp;
With obesity affecting nearly 42% of American adults and over 11 percent with diabetes, ensuring affordability poses a significant challenge.
A recent study by the Kaiser Family Foundation (KFF) revealed that approximately 3.6 million overweight or obese patients with heart conditions covered under the U.S. Medicare program may become eligible for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37984877/insurance-coverage-for-weight-loss-drugs-elevance-cvs-health-become-first-to-extend-coverage-to-n" rel="noreferrer noopener">coverage of Wegovy</a>.&nbsp;
The study highlights that the expanded coverage would affect Medicare beneficiaries and other insurers&#8217; coverage for individuals with heart conditions.&nbsp;
Currently,&nbsp;Medicare prescription drug plans (Part D) administered by private insurers do not cover drugs approved solely for obesity.&nbsp;
However, new guidance suggests that drugs approved for secondary use Medicare covers could be eligible.
Citing the KFF study, Reuters highlights that the approval could open up Wegovy to over a quarter of the 13.7 million Medicare beneficiaries diagnosed with heart disease and obesity.&nbsp;
Among these eligible patients, approximately 1.9 million also have diabetes, making them already eligible for Medicare coverage of other drugs like Novo&#8217;s Ozempic.
Although some Part D plans have announced plans to cover Wegovy this year, broader coverage may be anticipated by 2025.&nbsp;
The extent of the drug&#8217;s coverage and its impact on Medicare spending will depend on various factors. These include the number of Part D plans adding coverage, potential restrictions on use such as prior authorization, and negotiated prices paid by plans.
Despite major insurance plans covering these medications to varying extents, rising costs have led to coverage restrictions and termination, exacerbating accessibility issues.&nbsp;
Medicaid and Medicare coverage disparities further compound the problem.
Price Action:&nbsp;NVO shares are down 1.91% at $126.18&nbsp;at the last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photos courtesy: Shutterstock

<a href="https://www.nytimes.com/2024/04/24/well/live/ozempic-cost-senate.html?searchResultPosition=1">https://www.nytimes.com/2024/04/24/well/live/ozempic-cost-senate.html?searchResultPosition=1</a>
&nbsp;

"Senate Committee Investigates Ozempic And Wegovy Costs; Senator Bernie Sanders Is Pressing The Drugmaker Novo Nordisk For Details On Its Pricing Of The Popular Diabetes And Weight Loss Medications" - NY Times

A recent survey conducted by&nbsp;Morgan Stanley&nbsp;reveals that the use of GLP-1 drugs, popular for weight loss and diabetes, is affecting consumers&#8217; spending habits, particularly in&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/04/38063177/costco-long-known-for-rotisserie-chicken-and-hot-dogs-counters-junk-food-with-weight-loss-plan-to-he" rel="noreferrer noopener">the food industry</a>.&nbsp;
Novo Nordisk A/S&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegvoy (semaglutide) and&nbsp;Eli Lilly And Co&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound (tirzepatide) have amassed stupendous popularity as miracle weight loss drugs, as makers struggle to cope up with the demand.&nbsp;
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38320162/patients-find-weight-loss-drug-zepbound-a-game-changer-but-makers-see-production-delay-until-2025" rel="noreferrer noopener">Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025</a>.
The survey, involving 300 individuals currently on GLP-1 medication, indicates a significant decrease in appetite among users, leading to reduced spending on food in restaurants and grocery stores.
The survey findings suggest that most GLP-1 users are cutting back on dining out and ordering takeout, with 63% reporting reduced spending on restaurant meals.&nbsp;
Similarly, 61% mentioned spending less on deliveries or takeout, highlighting a shift in consumer behavior towards more frugal eating habits.
Although the increased demand for GLP-1 drugs poses potential challenges for food and beverage companies, CNBC, citing Morgan Stanley analysts,&nbsp;<a target="_blank" href="https://www.cnbc.com/2024/04/20/weight-loss-drug-patients-spend-less-on-restaurants-takeout-survey.html" rel="noreferrer noopener">highlights</a>&nbsp;that certain sectors are better positioned to navigate this shift.&nbsp;
Healthier fast-casual restaurants and coffee chains like&nbsp;Cava Group&nbsp;Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>),&nbsp;Chipotle Mexican Grill Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>),&nbsp;Sweetgreen Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>), and Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) are expected to fare better than traditional fast-food establishments.
On the other hand, packaged food companies like&nbsp;The Hershey Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) may face higher risks due to their focus on indulgent snacks.&nbsp;
However, according to the survey, companies offering healthier food options are likely to benefit from the rise in GLP-1 usage.
In addition to impacting food consumption, the survey also suggests a potential influence of GLP-1 drugs on addictive behaviors such as smoking.&nbsp;
A notable decline in both traditional cigarette and e-cigarette use was observed among respondents after starting GLP-1 treatment.
While the survey provides valuable insights into the changing consumption patterns associated with GLP-1 medications, Morgan Stanley remains cautious about drawing definitive conclusions regarding their&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38222006/novo-nordiskeli-lillys-weight-loss-drugs-does-not-cause-suicidal-behaviors-after-fda-european-med" rel="noreferrer noopener">impact on addictive behaviors</a>.&nbsp;
Ongoing medical research in this area will be crucial in understanding the full extent of GLP-1 effects.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by Vidmir Rais via Pixabay

Changing Frugal Eating Habits - How Novo Nordisk/Eli Lilly's Weight Loss Drugs Reshaping Food Spending

Thursday, Germany&#8217;s competition authority, Bundeskartellamt,&nbsp;<a target="_blank" href="https://www.bundeskartellamt.de/SharedDocs/Meldung/EN/Pressemitteilungen/2024/18_04_2024_Novo_Nordisk_Cardior.html?nn=48916" rel="noreferrer noopener">cleared</a>&nbsp;the planned acquisition of&nbsp;Cardior Pharmaceuticals GmbH&nbsp;by Danish pharma giant&nbsp;Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
Cardior is a biotech company focusing on heart diseases, in the case at hand cardiac insufficiency or heart failure.&nbsp;
The company has not yet offered any approved substances. Cardior&#8217;s main development product is an active substance against cardiac insufficiency caused by heart attacks.&nbsp;
In March, Novo Nordisk&nbsp;<a target="_blank" href="https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167038" rel="noreferrer noopener">agreed</a>&nbsp;to acquire Cardior for up to €1.025 billion. The agreement includes Cardior&#8217;s lead compound, CDR132L, which is currently in phase 2 clinical development for the treatment of heart failure.
The acquisition is an important step forward in Novo Nordisk&#8217;s strategy to establish a presence in cardiovascular disease.&nbsp;
&#8220;By welcoming Cardior as a part of Novo Nordisk, we will strengthen our pipeline of projects in cardiovascular disease where we already have ongoing programs across all phases of clinical development,&#8221; said Martin Holst Lange, executive vice president for Development at Novo Nordisk.&nbsp;
CDR132L is designed to halt and partially reverse cellular pathology by selectively blocking abnormal levels of the microRNA molecule miR-132. This could potentially lead to long-lasting improvement in heart function.
In a phase 1b trial published in the European Heart Journal, CDR132L was reported to be safe and well tolerated. The results suggested cardiac functional improvements in people with heart failure compared to placebo.&nbsp;
CDR132L is currently being investigated in the phase 2 trial HF-REVERT in 280 people with heart failure with reduced ejection fraction (HFrEF) who have previously suffered a heart attack (myocardial infarction). The first patient was dosed in the HF-REVERT trial in July 2022.
Novo Nordisk plans to initiate a second phase 2 trial that will investigate CDR132L in a chronic heart failure population with cardiac hypertrophy – a condition characterized by thick and stiff heart muscles.
The deal is expected to close in the second quarter of 2024.
Price Action: NVO shares are down 1.42% at $122.77 at the last check Thursday.
Photo via Shutterstock

German Authority Gives Go Ahead To Novo Nordisk's Small Bolt On Acquisition As Danish Firm Seeks To Build Heart Drugs Pipeline

The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says that? The companies that make those drugs predict.
The weight loss drug frenzy took off when the FDA&nbsp;<a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014" rel="noreferrer noopener">approved</a>&nbsp;Novo Nordisk A/S&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Wegvoy (semaglutide) in 2021.&nbsp;Eli Lilly And Co&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound (tirzepatide) appears to spur the momentum after receiving FDA&nbsp;<a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management" rel="noreferrer noopener">approval</a>&nbsp;in November 2023.
According to the FDA, limited supplies of Eli Lilly&#8217;s diabetes drug Mounjaro and weight-loss drug Zepbound are expected through the second quarter of this year&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36936648/whats-going-on-with-eli-lilly-stock-today" rel="noreferrer noopener">due to heightened demand</a>.&nbsp;
NBC&#8217;s Christine Romans reports for TODAY on how companies are trying to keep up with demand.
TODAY&#8217;s report notes that America&#8217;s relationship with weight loss is dramatically transforming as drugs from Eli and Novo Nordisk are changing the game.
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38223582/eli-lilly-suffers-legal-loss-for-its-popular-weight-lossdiabetes-drug-in-lawsuit-against-florida-" rel="noreferrer noopener">Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy</a>.
Sales surged to almost $11 billion in 2023 from $4 billion in 2022, and demand is outpacing supply.
In the North Carolina site, there is an all-hands-on-deck effort to increase the production of Eli Lilly&#8217;s Mounjaro for diabetes and Zepbound for weight loss.
The U.S. giant has injected multi-billion dollars into the new North Carolina facility to push out the medications in the market.
Edgardo Hernandez, Eli Lilly EVP &amp; Manufacturing operations resident, says the drugs will be available from the facility to the pharmacies in January 2025 or sometime next year.
The time is not soon enough, as roughly 80,000 people are taking Zepbound due to a shortage just five months after the FDA approved it.
Talking with TODAY,&nbsp;Rhonda Pacheco, US Lilly Diabetes &amp; Obesity Group Vice President, said it is the function of the massive demand that the makers are scrambling to keep up.
Pacheco added that there will be limited availability for the near term, which may cause delays across some of the doses for both Mounjaro and Zepbound.
The 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses of both drugs are particularly affected, while the 2.5 mg doses are available. Initially projected to be available in limited quantities through April, Mounjaro doses have been scarce&nbsp;<a target="_blank" href="https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Tirzepatide+Injection&amp;st=c&amp;tab=tabs-4&amp;panels=1" rel="noreferrer noopener">since</a>&nbsp;February.&nbsp;
When discussing outside of the near term, she adds that predicting when the supply will be full is very challenging.
Additionally, Trulicity (dulaglutide), another diabetes medication by Lilly, will see&nbsp;<a target="_blank" href="https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dulaglutide%20Injection&amp;st=c" rel="noreferrer noopener">restricted</a>&nbsp;availability of its 1.5 mg and 4.5 mg doses through April due to inc- patients are advised to plan for refills by contacting their pharmacy at least one week in advance.
&#8220;While we anticipate limited availability in the near term, we expect our investments in manufacturing and supply capacity to progressively increase production of our medicines throughout 2024 and beyond,&#8221; Reuter highlighted, citing Lilly&#8217;s spokesperson.
Price Action: LLY shares are down 0.14% at $749.71 on the last check Thursday.
Photo by Ciara Kimsey via Shutterstock

Patients Find Weight Loss Drug Zepbound A Game Changer, But Makers See Production Delay Until 2025

Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) with a Overweight and maintains $160 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

Watching Novo Nordisk; Traders Circulate Bloomberg Report 'Senators Seek Answers From Novo Nordisk About Levemir Drug'

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has outperformed the market over the past 5 years by 27.13% on an annualized basis producing an average annual return of 39.15%. Currently, Novo Nordisk has a market capitalization of $561.38 billion. 
Buying $1000 In NVO: If an investor had bought $1000 of NVO stock 5 years ago, it would be worth $5,184.96 today based on a price of $125.82 for NVO at the time of writing.
<h3>Novo Nordisk's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713196817_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $5,200 Today

BMO Capital Markets&nbsp;initiated coverage on Danish drug maker&nbsp;Novo Nordisk A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes drugs.&nbsp;
The analyst writes that an in-depth analysis of the growing obesity and adjacent metabolic disease market suggests&nbsp;Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Novo Nordisk will remain the two entrenched players in this duopoly.&nbsp;
While other players are just entering the obesity landscape, Novo has been established as a leader since Wegovy&#8217;s approval in 2021 (and Saxenda&#8217;s approval in 2014).&nbsp;
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38222006/novo-nordiskeli-lillys-weight-loss-drugs-does-not-cause-suicidal-behaviors-after-fda-european-med" rel="noreferrer noopener">Novo Nordisk/Eli Lilly&#8217;s Weight Loss Drugs Does Not Cause Suicidal Behaviors &#8211; After FDA, European Medicines Agency Says</a>.
Novo Nordisk&#8217;s decision to double down in obesity assets by developing therapeutics like CagriSema, GLP-1/GIPR agonists, and the new INV-202 has strengthened its pipeline in a market expected to grow to over $130 billion.
In the near term, BMO looks to Phase 3 REDEFINE trial results for CagriSema in obesity and Phase 3 STRIDE and SOUL results for semaglutide in Peripheral arterial disease (PAD) and type-2 diabetes (T2D) with chronic kidney disease (CKD)/ cardiovascular disease (CVD), respectively, to push shares higher.&nbsp;
Trials in secondary indications of obesity/T2D are expected to expand revenue and provide alternate paths to Medicare access.&nbsp;
BMO is initiating with an Outperform rating and a&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/NVO/analyst-ratings" rel="noreferrer noopener">price target of $163</a>.
Novo&#8217;s growing strength is fueled by various factors, including robust manufacturing, clinical and patient data, diverse pipelines, and enhanced access support, reinforcing the optimistic outlook on Novo Nordisk.&nbsp;
The company, along with Eli Lilly, dominates the market for incretin therapies, with demand rising steadily, especially after the approval of Wegovy.&nbsp;
Capacity limitations in the market, expected to persist until at least 2026, benefit both Novo and Lilly due to their substantial manufacturing capabilities, further bolstered by&nbsp;Catalent Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTLT#NYSE">CTLT</a>).&nbsp;
These constraints fortify Novo Nordisk&#8217;s competitive position, potentially impeding competitors even if they offer superior efficacy or tolerability.
Price Action: NVO shares are down 0.36% at $124.95 on the last check Friday.
Image Via Shutterstock

CTLT

Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating

U.S. District Judge Roy Altman&nbsp;<a target="_blank" href="https://cases.justia.com/federal/district-courts/florida/flsdce/1:2023cv23586/654456/46/0.pdf?ts=1712851105" rel="noreferrer noopener">ruled</a>&nbsp;that the drugmaker&nbsp;Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) cannot rely on state law to stop a compounding pharmacy,&nbsp;RXCompoundStore.com, from marketing its version of the drug tirzepatide.&nbsp;
Eli Lilly markets tirzepatide as Mounjaro for diabetes and Zepbound for weightloss.
According to Judge Altman, Lilly&#8217;s attempt to prevent this through the courts was seen as an effort to circumvent federal law.
&#8220;We think Eli Lilly is using state law to enforce the terms of the FDCA [Federal Food, Drug, and Cosmetic Act], which … is a task generally &#8216;reserve[d] to the FDA,'&#8221; Altman wrote, adding that the court will not allow Lilly &#8220;to use state law as a back door to private enforce the FDCA.&#8221;
&#8220;As the Supreme Court has made clear, &#8216;the FDCA and its regulations provide the United States with nearly exclusive enforcement authority,'&#8221; the judge&#8217;s ruling states. &#8220;Given the federal government&#8217;s &#8216;nearly exclusive&#8217; authority to enforce the FDCA, courts around the country have generally refused to encroach on that authority by adjudicating claims that a party has (or has not) complied with the FDCA.&#8221;
In September 2023, Eli Lilly announced legal action against ten entities in the U.S., including medical spas, wellness centers, and compounding pharmacies, alleging that they have been selling unauthorized, less expensive&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/09/34757757/eli-lilly-cracks-down-on-counterfeit-mounjaro-weight-loss-and-diabetes-drugs-sues-lawsuit-against" rel="noreferrer noopener">versions of Mounjaro</a>.
In March, the U.S. pharma giant revealed that it has identified bacteria and elevated impurity levels in products falsely claiming to be compounded versions of tirzepatide, the active ingredient in its widely-used diabetes medication Mounjaro and the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37544347/eli-lillys-legal-battle-against-fake-compounded-tirzepatide-products-bacteria-impurities-detected" rel="noreferrer noopener">weight loss treatment Zepbound</a>.&nbsp;
Lilly competitor Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), which markets Ozempic and Wegovy, has also been going after compounding pharmacies and wellness clinics for selling altered versions of semaglutide.&nbsp;
In November 2023,&nbsp;Novo Nordisk announced a&nbsp;legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their products claiming to contain the active ingredient, semaglutide, for its popular&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/06/32929431/novo-nordisk-takes-legal-action-against-wellness-clinics-for-false-advertising-of-weight-loss-dru" rel="noreferrer noopener">weight-loss drug Wegovy</a>.&nbsp;
The Danish drugmaker found these impurities to be as high as 33% in some instances, raising concerns about the safety and efficacy of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/36020513/novo-nordisk-sues-florida-compounding-pharmacies-over-impurities-in-products-claiming-to-contain-" rel="noreferrer noopener">the compounded drugs</a>.
Price Action: LLY shares are up 0.15% at $760.76 on the last check Friday.
Wegovy. Image Via Shutterstock

Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy

The European Medicines Agency&#8217;s Pharmacovigilance Risk Assessment Committee (PRAC) has&nbsp;<a target="_blank" href="https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024" rel="noreferrer noopener">determined</a>&nbsp;that there is no substantial evidence supporting a link between Glucagon-Like Peptide-1 receptor agonists (GLP-1) and suicidal or self-injurious thoughts and behaviors.&nbsp;
The assessment comes following reports of suicidal thoughts or actions. The FDA also conducted a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36509636/novo-nordisks-ozempic-and-wegovy-helps-lose-weight-not-ones-mind-us-study-find-no-increased-suici" rel="noreferrer noopener">review of GLP-1 RAs</a>.
The FDA released an update stating that its preliminary review did not show definitive evidence that the drugs cause&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/01/36602710/fda-finds-no-evidence-weight-loss-drugs-cause-suicidal-thoughts" rel="noreferrer noopener">suicidal thoughts or actions</a>.
GLP-1 receptor agonists, including dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide, are commonly prescribed for treating type 2 diabetes and, under specific conditions, for managing weight in obese or overweight adults.
The review was initiated in July 2023, prompted by reports of suicidal ideation among users of liraglutide and semaglutide medications.&nbsp;
In November 2023, the committee&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36046376/weight-loss-drugs-and-associated-suicidal-thoughts-european-drug-regulator-seeks-clarifications-f" rel="noreferrer noopener">requested additional data</a>&nbsp;from the marketing authorization holders for these medications, including&nbsp;Novo Nordisk A/S&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) Ozempic, Rybelsus, Wegovy, Saxenda, Victoza, and Xultophy;&nbsp;AstraZeneca Plc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) Byetta and Bydureon;&nbsp;Sanofi SA&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Lyxumia, and Suliqua; and&nbsp;Eli Lilly And Co&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Trulicity.&nbsp;
Furthermore, the committee scrutinized the outcomes of a recent study based on a vast electronic health records database.&nbsp;
This study, which investigated the incidence of suicidal ideation in overweight patients with type 2 diabetes receiving semaglutide or other non-GLP-1 receptor agonist medications, found no direct link between semaglutide usage and suicidal thoughts.
The EMA conducted a study using electronic health records to investigate the risk of suicide and self-injury in people with type 2 diabetes using GLP-1 receptor agonists.&nbsp;
They found no evidence establishing a direct link between these medications and the mentioned risks.&nbsp;
Following a review of various data sources, including non-clinical studies, clinical trials, and post-marketing surveillance data, the PRAC concluded that no revision to the product information is necessary.&nbsp;
The PRAC determined that no changes to the product information are needed. The medication companies will continue monitoring these events and updating their safety reports accordingly.&nbsp;
Additionally, the PRAC approved a communication plan to inform healthcare professionals about differences between current and proposed formulations of Rybelsus, an oral semaglutide medication for poorly controlled type 2 diabetes.
Price Action: NVO shares are up 0.41% at $125.91 on the last check Friday.
Image By Natalia Varlei On Shutterstock

Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says

WIIM

Novo Nordisk shares are trading higher after EU regulators reportedly ruled out a link between wight loss drugs and suicidal thoughts. Additionally, BMO Capital initiated coverage on the stock with an Outperform rating.

The&nbsp;PRAC&nbsp;has concluded that the available evidence does not support a causal association between the Glucagon-Like Peptide-1 receptor agonists (GLP-1) &ndash; dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide &ndash; and suicidal and self-injurious thoughts and actions.
GLP-1 receptor agonists are used to treat type 2 diabetes and some are also authorised for weight management under certain conditions in adults who are obese or overweight. The review started in July 2023, following case reports of suicidal thoughts and thoughts of self-injury from people using liraglutide and semaglutide medicines, and in November 2023 the committee requested additional data from the&nbsp;marketing authorisation holders&nbsp;for these medicines, namely Ozempic, Rybelsus, Wegovy, Victoza, Saxenda, Xultophy, Byetta, Bydureon, Lyxumia, Suliqua and Trulicity.
Additionally, the committee analysed the results of a recent study1, based on a large database of electronic health records, which investigated the incidence of suicidal thoughts in patients with overweight and type 2 diabetes mellitus treated with semaglutide or other non-GLP-1 receptor agonist medicines for diabetes or overweight. The study found no causal association between the use of semaglutide and suicidal thoughts.
Another study was conducted by EMA2, based on electronic health records, which examined the risk of suicide-related and self-injury-related events in people with type 2 diabetes mellitus. The results did not support a causal association between the use of GLP-1 receptor agonists and this risk.
After reviewing the available evidence from non-clinical studies,&nbsp;clinical trials, post-marketing surveillance data and the available studies the&nbsp;PRAC&nbsp;considers that no update to the&nbsp;product information&nbsp;is warranted.
The&nbsp;marketing authorisation holders&nbsp;for these medicines will continue to monitor these events closely, including any new publications, as part of their&nbsp;pharmacovigilance&nbsp;activities and report any new evidence on this issue in their&nbsp;Periodic Safety Update Reports&nbsp;(PSURs).

Government

Regulations

Pharmacovigilance Risk Assessment Committee Clears GLP-1 Diabetes Medications of Causing Suicidal or Self-Injurious Behavior

BMO Capital analyst Evan David Seigerman initiates coverage on Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) with a Outperform rating and announces Price Target of $163.

Initiation

BMO Capital Initiates Coverage On Novo Nordisk with Outperform Rating, Announces Price Target of $163

Ginkgo Bioworks Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNA#NASDAQ">DNA</a>) shares are volatile Thursday. The company announced the acquisition of AgBiome&#8217;s platform assets and the expansion of its <a href="https://www.benzinga.com/pressreleases/24/04/n38179114/ginkgo-bioworks-and-novo-nordisk-expand-alliance-to-collaborate-across-r-d-value-chain">strategic partnership with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).&nbsp;</a>
The Details:
Ginkgo Bioworks said the <a href="https://www.benzinga.com/pressreleases/24/04/n38198673/ginkgo-bioworks-announces-acquisition-of-agbiomes-platform-assets">assets acquired</a> from AgBiome include over 115,000 sequenced and isolated strains, over 500 million unique gene sequences, and relevant functional data and metadata.&nbsp;
&#8220;We are so excited to bring AgBiome&#8217;s incredible strain and metagenomic collection into Ginkgo. This is a world class asset that will significantly expand our capabilities and can directly benefit Ginkgo&#8217;s customers in the ag biologicals space. In addition to the platform assets and capabilities, the product concepts pipeline that has been validated by AgBiome to date provides an exciting opportunity to give customers a head-start in their product development efforts,&#8221; said Michael Miille, Ginkgo Fellow.&nbsp;
Ginkgo Bioworks announced the expansion of its strategic partnership with Novo Nordisk A/S on Wednesday under a framework agreement that initially is contemplated to run over five years.Ginkgo said the partnership aim to improve the manufacturing of Novo Nordisk&#8217;s medicines for serious chronic diseases, including diabetes and obesity medications.
&#8220;Novo Nordisk has played an important role in shaping the landscape for pharmaceutical products in the 21st century. We&#8217;re so excited to expand our partnership to help them achieve their ambitious and global goals. With this deal structure, Novo Nordisk can easily access the entire expanse of Ginkgo&#8217;s pharma services from discovery through manufacturing," said Jason Kelly, Ginkgo CEO.&nbsp;
Related News: <a href="https://www.benzinga.com/news/24/04/38171000/whats-going-on-with-chinese-ev-stocks-nio-and-xpeng">What&#8217;s Going On With Chinese EV Stocks Nio And XPeng?</a>
<h2 class="wp-block-heading">How To Buy DNA Stock:</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Ginkgo Bioworks Holdings&#8217; case, it is in the Materials sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
DNA Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Ginkgo Bioworks shares are down 7.1% at $1.04 at the time of publication Thursday.
Image: Markus Distelrath from Pixabay

What's Going On With Ginkgo Bioworks Stock?

Contracts

Ginkgo Bioworks Announced The Expansion Of Its Strategic Partnership With Novo Nordisk Under A Framework Agreement That Initially Is Contemplated To Run Over Five Years

Novo Nordisk (NVO) has released an update. Novo Nordisk A/S has updated its Articles of Association, maintaining a commitment to research, developm...

Novo Nordisk Updates Corporate Governance Structure

Novo Nordisk (NVO) has released an update. Novo Nordisk A/S has announced a reduction in its B share capital following the Annual General Meeting d...

Novo Nordisk Executes Share Capital Reduction

Novo Nordisk (NVO) has released an update. Novo Nordisk A/S has updated its shareholders on the latest changes to its share capital and voting righ...

Novo Nordisk Shares Capital and Voting Rights Update

AstraZeneca: Strong In A Weak Market

Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy

ClearBridge Global Growth Strategy Q1 2024 Portfolio Manager Commentary

What do weight-loss drugs mean for the diet industry?

Artisan International Explorer Fund Q1 2024 Commentary

Eli Lilly raises guidance on weight loss momentum

Novo, Teva, AstraZeneca issued FTC warnings over 'bogus' patents

AAPL

ABBV

AMPH

AMZN

ASML

AVGO

BGNE

CACG

CFCV

CMSQF

CMSQY

DAIUF

DESP

DFKCY

DSKYF

DSNKY

EDNMF

EDNMY

EENNF

EQBBF

GOOGL

GWRE

HAGHY

HNSDF

INFR

IQEPF

IQEPY

LRGE

MDMXF

MLTX

MNDY

MSFT

NONOF

NVDA

NVSEF

ODFL

PGPEF

PUBGY

QUCOF

SDXAY

SDXOF

TEVA

TSYHF

TSYHY

WDAY

XROLF

YLDE

ZLAB

ZLDPF

Opinion

Press Releases

Thinking about trading options or stock in Tesla, Microsoft, Novo Nordisk, Intel, or Solaredge Technologies?

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Thinking about trading options or stock in Oracle, Cardinal Health, Hewlett Packard Enterprise, Novo Nordisk, or Victoria's Secret?

Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity

Thinking about trading options or stock in Apple, Pfizer, Taiwan Semiconductor, Microsoft, or Novo Nordisk?

Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum

Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave

Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey

Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty

Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)

ARGX

ATNM

BNTX

BTTX

INTC

MRNA

ORCL

REGN

SEDG

TSLA

VRTX

VSCO

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Indivior

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly and Co

Merck & Co

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Novo Nordisk Stock (NYSE:NVO), Short Interest Report

People Also Watch